Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Former Bank of England Official Bradley Fried To Chair Goldman Sachs International – $GS $DIS $INVO

By John F. Heerdink, Jr.

Reportedly, former Chair of the Court of the Bank of England, Bradley Fried, has been appointed as the chairman of Goldman Sachs (GS) International. Fried will replace Jose Manuel Barroso, who was the former European Commission president. Fried is expected to assume his role in February next year.

Bradley Fried’s term of appointment as Chair of Court of the Bank of England was effective from 1 July 2018 – June 2022. Bradley Fried is a co-founder of Grovepoint Capital LLP, prior to which he was Chief Executive Officer of Investec Bank plc. Before joining Investec in 1999, Brad was a partner at McKinsey & Co. in New York where he focused on strategy consulting to the financial services industry. Brad holds an MBA from the Wharton School of the University of Pennsylvania, and is a qualified chartered accountant CA(SA) having trained with Arthur Andersen in South Africa. Brad is a Governor at the London Business School and a Fellow at Magdalene College, Cambridge.


The Goldman Sachs Group, Inc. (GS) is one of the world’s leading investment bankers & also a securities and investment management firm that offers a wide range of financial services with a diversified client base. To learn more about The Goldman Sachs Group, Inc. (GS) and to continue to track its progress please visit the Vista Partners Goldman Sachs Group, Inc. (GS), Coverage Page

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: UPDATE 1-Goldman taps former BoE official Bradley Fried as next International chair- Sky News in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us